Hookipa Pharma Inc (HOOK) Stock
HOOK is no longer traded. Hookipa Pharma was delisted from the Nasdaq in June 2026.
Prices on this page are historical; the last trade was June 2, 2026 at $1.15.
Hookipa Pharma stock price history
HOOK final trading statistics
- Final close
- $1.15
- Final trading day
- Jun 2, 2026
- Market cap at delisting
- $11.47M
- Shares outstanding
- 9.98M
- Final 52-week range
- $0.81 – $1.65
- Avg. volume (final 3 mo.)
- 12,475
- All-time high (split-adj.)
- $195.10 · May 2021
- All-time low (split-adj.)
- $0.74 · Apr 2025
- Return since IPO
- -99.2%
- Beta
- 0.83
- Book value / share
- $2.71
- Price / book
- 0.42
Hookipa Pharma annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $9.70M | -$13.8M | — |
| FY2024 | $43.95M | -$43.5M | -$3.25 |
| FY2023 | $20.13M | -$81.6M | -$0.88 |
| FY2022 | $14.25M | -$65.1M | -$1.05 |
| FY2021 | $18.45M | -$75.7M | -$2.31 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Hookipa Pharma Inc
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Hookipa Pharma stock FAQ
What happened to Hookipa Pharma stock?
Hookipa Pharma stock was delisted from the Nasdaq. Its final close was $1.15 on June 2, 2026.
Is HOOK stock still trading?
No. HOOK was delisted from the Nasdaq in June 2026 and no longer trades on a U.S. exchange.
What was the last price of HOOK stock?
HOOK closed at $1.15 on its final trading day, June 2, 2026, for a market value of about $11.47M.
What were Hookipa Pharma's revenue and earnings in its last full fiscal year?
Hookipa Pharma reported revenue of $9.70M and net income of -$13.8M in fiscal 2025, its last full year as a public company.
When did Hookipa Pharma go public?
Hookipa Pharma Inc stock began trading on April 18, 2019.